VATI PN Pharmacology Actual Exam | NGN-Style Questions |
2026/2027 Edition | 250 Verified Questions
VATI PN Pharmacology Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest NGN Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified NGN-style questions covering
all major pharmacology topics for the VATI PN exam. Each question includes detailed rationales and
distractors to enhance understanding. Designed for nursing students seeking to master pharmacological
principles and achieve a high score. Updated for the 2026/2027 academic year to reflect the latest
NCLEX-PN and VATI testing standards.
Key Features:
Pharmacokinetics and pharmacodynamics
Medication administration and safety
Cardiovascular and respiratory medications
Neurological and psychiatric medications
Endocrine and gastrointestinal medications
Antibiotics, antivirals, and antifungals
Updates for 2026:
- Incorporated 2026 NGN clinical judgment scenarios
- Revised rationales to align with current evidence-based practice
- Added new questions on COVID-19 treatments and vaccines
- Updated drug classifications per latest FDA approvals
- Enhanced distractor explanations for improved critical thinking
Abstract:
This exam preparation resource provides 250 NGN-style questions specifically tailored for the VATI PN
Pharmacology exam. The content is organized by major drug classes and body systems, emphasizing clinical
application and safety. Each question is accompanied by a detailed rationale explaining the correct answer and
common misconceptions. The document reflects the 2026/2027 curriculum updates, including new medications and
guidelines. Designed to simulate the actual exam experience, it helps students build confidence and competence in
pharmacology. Ideal for self-assessment and focused review before the VATI PN assessment.
Keywords:
VATI PN Pharmacology, NGN-style questions, nursing exam prep, pharmacology rationales, medication safety,
NCLEX-PN review, drug classifications, clinical judgment
Answer Format:
Each question is followed by the correct answer, a detailed rationale explaining the underlying pharmacology, and
analysis of incorrect distractors. Rationales highlight key concepts and clinical reasoning to reinforce learning.
Compliance Checklist:
All questions align with 2026 NGN test plan
Rationales cite current pharmacology references
Distractors represent common student errors
Content covers all major VATI PN pharmacology domains
Updated for 2026/2027 academic year
Verified by nursing education experts
Page 1
,Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics & 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion, receptor theory, dose-response
Medication Administration & 41-80 Routes, calculations, rights of 16%
Safety administration, adverse effects, interactions
Cardiovascular & Respiratory 81-120 Antihypertensives, antiarrhythmics, 16%
Medications diuretics, bronchodilators, anticoagulants
Neurological & Psychiatric 121-160 Antidepressants, antipsychotics, 16%
Medications anticonvulsants, analgesics, sedatives
Endocrine & Gastrointestinal 161-200 Insulin, oral hypoglycemics, thyroid drugs, 16%
Medications antacids, antiemetics
Antibiotics, Antivirals, & 201-250 Penicillins, cephalosporins, macrolides, 20%
Antifungals antivirals, antifungals, resistance
Page 2
,Q1. A patient receiving a continuous intravenous infusion of heparin develops a sudden onset of
shortness of breath, chest pain, and hypotension. Laboratory results show a platelet count of
45,000/mm³. Which antibody complex is most likely responsible for this reaction?
A. IgG-heparin complex binding to platelet factor 4
B. IgE-heparin complex binding to mast cells
C. IgM-heparin complex activating complement
D. IgA-heparin complex causing platelet aggregation
Correct Answer: A. IgG-heparin complex binding to platelet factor 4
Rationale: Heparin-induced thrombocytopenia (HIT) type II is caused by IgG antibodies that bind to
heparin complexed with platelet factor 4 (PF4). These immune complexes activate platelets via FcIIa
receptors, leading to thrombosis and thrombocytopenia. Option B describes a type I hypersensitivity, not
HIT. Option C involves IgM, which is not typical for HIT. Option D involves IgA, which is not implicated
in HIT.
Why Wrong:
B - IgE-mediated reactions are associated with immediate hypersensitivity, not HIT.
C - IgM is not the primary antibody class involved in HIT; IgG is predominant.
D - IgA antibodies are not known to mediate HIT; the classic mechanism involves IgG.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q2. A patient with type 2 diabetes mellitus is prescribed metformin. Which mechanism best explains
the drug's ability to lower blood glucose without causing hypoglycemia?
A. Stimulates insulin secretion from pancreatic beta cells
B. Increases peripheral glucose uptake and decreases hepatic gluconeogenesis
C. Delays carbohydrate absorption from the gastrointestinal tract
D. Enhances endogenous insulin sensitivity and promotes glucagon release
Correct Answer: B. Increases peripheral glucose uptake and decreases hepatic gluconeogenesis
Rationale: Metformin primarily reduces hepatic glucose production (gluconeogenesis) and increases
insulin-mediated glucose uptake in peripheral tissues. It does not stimulate insulin secretion, which is why
it rarely causes hypoglycemia. Option A describes sulfonylureas. Option C describes alpha-glucosidase
inhibitors. Option D is incorrect because metformin does not promote glucagon release.
Why Wrong:
A - Metformin does not stimulate insulin secretion; that is the action of sulfonylureas.
C - Delaying carbohydrate absorption is the mechanism of alpha-glucosidase inhibitors, not
metformin.
D - Metformin improves insulin sensitivity but does not promote glucagon release; glucagon raises
blood glucose.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48
Page 3
, Q3. Which of the following drug combinations poses the greatest risk of serotonin syndrome?
A. Warfarin and aspirin
B. Lithium and furosemide
C. Phenelzine and meperidine
D. Digoxin and amiodarone
Correct Answer: C. Phenelzine and meperidine
Rationale: Phenelzine (MAOI) and meperidine (opioid) both increase serotonin activity. Their
combination can lead to serotonin syndrome, characterized by hyperthermia, rigidity, and autonomic
instability. Warfarin and aspirin increase bleeding risk. Lithium and furosemide can cause lithium toxicity
due to sodium depletion. Digoxin and amiodarone increase digoxin levels due to P-glycoprotein
inhibition.
Why Wrong:
A - This combination increases bleeding risk, not serotonin syndrome.
B - This combination increases risk of lithium toxicity, not serotonin syndrome.
D - This combination increases digoxin toxicity risk, not serotonin syndrome.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16, 30
Q4. A patient inadvertently receives a dose of naloxone. Which physiologic effect is most likely to
occur?
A. Respiratory depression
B. Miosis
C. Increased pain perception
D. Euphoria
Correct Answer: C. Increased pain perception
Rationale: Naloxone is an opioid antagonist that rapidly reverses opioid effects. In opioid-tolerant
patients, it can precipitate acute withdrawal and increase pain perception due to blockade of endogenous
opioid receptors. Respiratory depression is reversed, not caused. Miosis is an opioid effect that is
reversed. Euphoria is an opioid effect, not caused by naloxone.
Why Wrong:
A - Naloxone reverses respiratory depression, it does not cause it.
B - Naloxone reverses miosis, it does not cause pupillary constriction.
D - Naloxone does not produce euphoria; it blocks opioid receptors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 13
Page 4
2026/2027 Edition | 250 Verified Questions
VATI PN Pharmacology Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest NGN Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified NGN-style questions covering
all major pharmacology topics for the VATI PN exam. Each question includes detailed rationales and
distractors to enhance understanding. Designed for nursing students seeking to master pharmacological
principles and achieve a high score. Updated for the 2026/2027 academic year to reflect the latest
NCLEX-PN and VATI testing standards.
Key Features:
Pharmacokinetics and pharmacodynamics
Medication administration and safety
Cardiovascular and respiratory medications
Neurological and psychiatric medications
Endocrine and gastrointestinal medications
Antibiotics, antivirals, and antifungals
Updates for 2026:
- Incorporated 2026 NGN clinical judgment scenarios
- Revised rationales to align with current evidence-based practice
- Added new questions on COVID-19 treatments and vaccines
- Updated drug classifications per latest FDA approvals
- Enhanced distractor explanations for improved critical thinking
Abstract:
This exam preparation resource provides 250 NGN-style questions specifically tailored for the VATI PN
Pharmacology exam. The content is organized by major drug classes and body systems, emphasizing clinical
application and safety. Each question is accompanied by a detailed rationale explaining the correct answer and
common misconceptions. The document reflects the 2026/2027 curriculum updates, including new medications and
guidelines. Designed to simulate the actual exam experience, it helps students build confidence and competence in
pharmacology. Ideal for self-assessment and focused review before the VATI PN assessment.
Keywords:
VATI PN Pharmacology, NGN-style questions, nursing exam prep, pharmacology rationales, medication safety,
NCLEX-PN review, drug classifications, clinical judgment
Answer Format:
Each question is followed by the correct answer, a detailed rationale explaining the underlying pharmacology, and
analysis of incorrect distractors. Rationales highlight key concepts and clinical reasoning to reinforce learning.
Compliance Checklist:
All questions align with 2026 NGN test plan
Rationales cite current pharmacology references
Distractors represent common student errors
Content covers all major VATI PN pharmacology domains
Updated for 2026/2027 academic year
Verified by nursing education experts
Page 1
,Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics & 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion, receptor theory, dose-response
Medication Administration & 41-80 Routes, calculations, rights of 16%
Safety administration, adverse effects, interactions
Cardiovascular & Respiratory 81-120 Antihypertensives, antiarrhythmics, 16%
Medications diuretics, bronchodilators, anticoagulants
Neurological & Psychiatric 121-160 Antidepressants, antipsychotics, 16%
Medications anticonvulsants, analgesics, sedatives
Endocrine & Gastrointestinal 161-200 Insulin, oral hypoglycemics, thyroid drugs, 16%
Medications antacids, antiemetics
Antibiotics, Antivirals, & 201-250 Penicillins, cephalosporins, macrolides, 20%
Antifungals antivirals, antifungals, resistance
Page 2
,Q1. A patient receiving a continuous intravenous infusion of heparin develops a sudden onset of
shortness of breath, chest pain, and hypotension. Laboratory results show a platelet count of
45,000/mm³. Which antibody complex is most likely responsible for this reaction?
A. IgG-heparin complex binding to platelet factor 4
B. IgE-heparin complex binding to mast cells
C. IgM-heparin complex activating complement
D. IgA-heparin complex causing platelet aggregation
Correct Answer: A. IgG-heparin complex binding to platelet factor 4
Rationale: Heparin-induced thrombocytopenia (HIT) type II is caused by IgG antibodies that bind to
heparin complexed with platelet factor 4 (PF4). These immune complexes activate platelets via FcIIa
receptors, leading to thrombosis and thrombocytopenia. Option B describes a type I hypersensitivity, not
HIT. Option C involves IgM, which is not typical for HIT. Option D involves IgA, which is not implicated
in HIT.
Why Wrong:
B - IgE-mediated reactions are associated with immediate hypersensitivity, not HIT.
C - IgM is not the primary antibody class involved in HIT; IgG is predominant.
D - IgA antibodies are not known to mediate HIT; the classic mechanism involves IgG.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36
Q2. A patient with type 2 diabetes mellitus is prescribed metformin. Which mechanism best explains
the drug's ability to lower blood glucose without causing hypoglycemia?
A. Stimulates insulin secretion from pancreatic beta cells
B. Increases peripheral glucose uptake and decreases hepatic gluconeogenesis
C. Delays carbohydrate absorption from the gastrointestinal tract
D. Enhances endogenous insulin sensitivity and promotes glucagon release
Correct Answer: B. Increases peripheral glucose uptake and decreases hepatic gluconeogenesis
Rationale: Metformin primarily reduces hepatic glucose production (gluconeogenesis) and increases
insulin-mediated glucose uptake in peripheral tissues. It does not stimulate insulin secretion, which is why
it rarely causes hypoglycemia. Option A describes sulfonylureas. Option C describes alpha-glucosidase
inhibitors. Option D is incorrect because metformin does not promote glucagon release.
Why Wrong:
A - Metformin does not stimulate insulin secretion; that is the action of sulfonylureas.
C - Delaying carbohydrate absorption is the mechanism of alpha-glucosidase inhibitors, not
metformin.
D - Metformin improves insulin sensitivity but does not promote glucagon release; glucagon raises
blood glucose.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48
Page 3
, Q3. Which of the following drug combinations poses the greatest risk of serotonin syndrome?
A. Warfarin and aspirin
B. Lithium and furosemide
C. Phenelzine and meperidine
D. Digoxin and amiodarone
Correct Answer: C. Phenelzine and meperidine
Rationale: Phenelzine (MAOI) and meperidine (opioid) both increase serotonin activity. Their
combination can lead to serotonin syndrome, characterized by hyperthermia, rigidity, and autonomic
instability. Warfarin and aspirin increase bleeding risk. Lithium and furosemide can cause lithium toxicity
due to sodium depletion. Digoxin and amiodarone increase digoxin levels due to P-glycoprotein
inhibition.
Why Wrong:
A - This combination increases bleeding risk, not serotonin syndrome.
B - This combination increases risk of lithium toxicity, not serotonin syndrome.
D - This combination increases digoxin toxicity risk, not serotonin syndrome.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16, 30
Q4. A patient inadvertently receives a dose of naloxone. Which physiologic effect is most likely to
occur?
A. Respiratory depression
B. Miosis
C. Increased pain perception
D. Euphoria
Correct Answer: C. Increased pain perception
Rationale: Naloxone is an opioid antagonist that rapidly reverses opioid effects. In opioid-tolerant
patients, it can precipitate acute withdrawal and increase pain perception due to blockade of endogenous
opioid receptors. Respiratory depression is reversed, not caused. Miosis is an opioid effect that is
reversed. Euphoria is an opioid effect, not caused by naloxone.
Why Wrong:
A - Naloxone reverses respiratory depression, it does not cause it.
B - Naloxone reverses miosis, it does not cause pupillary constriction.
D - Naloxone does not produce euphoria; it blocks opioid receptors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 13
Page 4
